MCID: VSC007
MIFTS: 68

Vascular Disease

Categories: Mental diseases, Gastrointestinal diseases, Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Vascular Disease

Summaries for Vascular Disease

MedlinePlus : 43 The vascular system is the body's network of blood vessels. It includes the arteries, veins and capillaries that carry blood to and from the heart. Problems of the vascular system are common and can be serious. Arteries can become thick and stiff, a problem called atherosclerosis. Blood clots can clog vessels and block blood flow to the heart or brain. Weakened blood vessels can burst, causing bleeding inside the body. You are more likely to have vascular disease as you get older. Other factors that make vascular disease more likely include Family history of vascular or heart diseases Pregnancy Illness or injury Long periods of sitting or standing still Any condition that affects the heart and blood vessels, such as diabetes or high cholesterol Smoking Obesity Losing weight, eating healthy foods, being active and not smoking can help vascular disease. Other treatments include medicines and surgery.

MalaCards based summary : Vascular Disease, also known as vascular diseases, is related to peripheral vascular disease and hepatic vascular disease, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Vascular Disease is MIR145 (MicroRNA 145
Phenotypic modulation of vascular smooth muscle cells (VSMCs) plays a critical role in the pathogenesis of a variety of proliferative vascular diseases. Recently, we have found that microRNA (miRNA) miR-145 is the most abundant miRNA in normal vascular walls and in freshly isolated VSMCs; however, the role of miR-145 in VSMC phenotypic modulation and vascular diseases is currently unknown. Here we find that miR-145 is selectively expressed in VSMCs of the vascular wall and its expression is significantly downregulated in the vascular walls with neointimal lesion formation and in cultured dedifferentiated VSMCs. More importantly, both in cultured rat VSMCs in vitro and in balloon-injured rat carotid arteries in vivo, we demonstrate that the noncoding RNA miR-145 is a novel phenotypic marker and a novel phenotypic modulator of VSMCs. VSMC differentiation marker genes such as SM alpha-actin, calponin, and SM-MHC are upregulated by premiR-145 or adenovirus expressing miR-145 (Ad-miR-145) but are downregulated by the miR-145 inhibitor 2'OMe-miR-145. We have further identified that miR-145-mediated phenotypic modulation of VSMCs is through its target gene KLF5 and its downstream signaling molecule, myocardin. Finally, restoration of miR-145 in balloon-injured arteries via Ad-miR-145 inhibits neointimal growth. We conclude that miR-145 is a novel VSMC phenotypic marker and modulator that is able of controlling vascular neointimal lesion formation. These novel findings may have extensive implications for the diagnosis and therapy of a variety of proliferative vascular diseases.), and among its related pathways/superpathways are Fluid shear stress and atherosclerosis and Folate Metabolism. The drugs Methyltestosterone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A cardiovascular system disease that primarily affects the blood vessels which includes the arteries, veins and capillaries that carry blood to and from the heart.

Wikipedia : 76 Vascular disease is a class of diseases of the blood vessels – the arteries and veins of the circulatory... more...

Related Diseases for Vascular Disease

Diseases related to Vascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 381)
# Related Disease Score Top Affiliating Genes
1 peripheral vascular disease 35.7 ACE CRP SELP SERPINE1 VCAM1 VEGFA
2 hepatic vascular disease 35.3 EDN1 MTHFR NOS3 SERPINE1
3 retinal vascular disease 35.1 INS MTHFR VEGFA
4 buerger disease 34.4 MTHFR NOS3 SERPINE1
5 arteriosclerosis 33.6 ACE APOE CRP EDN1 INS PON1
6 ischemia 33.4 ACE EDN1 NOS3 PON1 SELP VEGFA
7 thrombosis 33.2 MTHFR SELP SERPINE1
8 renal artery disease 32.9 ACE NOS3
9 intermittent claudication 32.7 ACE CRP SELP SERPINE1 VEGFA
10 arteries, anomalies of 32.4 ACE ACVRL1 APOE CRP EDN1 INS
11 chronic thromboembolic pulmonary hypertension 32.4 CRP EDN1
12 chronic kidney failure 31.8 ACE CRP EDN1 INS VCAM1
13 kidney disease 31.8 ACE APOE CRP EDN1 INS
14 coronary heart disease 1 31.7 ACE APOE CRP INS PON1 SERPINE1
15 homocysteinemia 31.7 CBS CRP MTHFR NOS3
16 limb ischemia 31.6 ACE EDN1 NOS3 VEGFA
17 diabetes mellitus 31.6 ACE CRP EDN1 INS MIR145 NOS3
18 peripheral artery disease 31.6 ACE CRP NOS3 SELP VCAM1 VEGFA
19 carotid stenosis 31.5 ACE APOE CRP MTHFR SELP
20 angina pectoris 31.4 ACE CRP EDN1 NOS3 SERPINE1
21 ischemic heart disease 31.4 ACE APOE CRP INS NOS3
22 vascular dementia 31.3 ACE APOE MTHFR PON1 VEGFA
23 hypercholesterolemia, familial 31.3 APOE CRP INS NOS3 PON1
24 pre-eclampsia 31.3 EDN1 MTHFR NOS3 SELP SERPINE1 VCAM1
25 retinal vein occlusion 31.3 MTHFR SERPINE1 VEGFA
26 carotid artery disease 31.3 ACE APOE CRP
27 renovascular hypertension 31.2 ACE EDN1 NOS3
28 sleep apnea 31.2 ACE APOE CRP EDN1 INS NOS3
29 cerebral atherosclerosis 31.2 ACE APOE MTHFR
30 hypertension, essential 31.2 ACE CRP EDN1 INS NOS3 SELP
31 cerebrovascular disease 31.1 ACE APOE CBS CRP INS MTHFR
32 diabetes mellitus, noninsulin-dependent 31.1 ACE APOE CRP EDN1 INS MIR125A
33 venous insufficiency 31.1 CRP SELP SERPINE1 VCAM1
34 coronary artery anomaly 31.1 ACE APOE CBS CRP EDN1 INS
35 ischemic optic neuropathy 31.1 ACE EDN1 MTHFR NOS3
36 idiopathic interstitial pneumonia 31.1 EDN1 SERPINE1 VEGFA
37 microvascular complications of diabetes 3 31.1 ACE INS MIR21
38 pulmonary edema 31.0 ACE CRP EDN1 NOS3
39 chronic venous insufficiency 31.0 SELP SERPINE1 VCAM1
40 microvascular complications of diabetes 5 31.0 ACE INS NOS3 PON1 SERPINE1 VCAM1
41 osteonecrosis 31.0 MTHFR SERPINE1 VEGFA
42 thrombophilia due to thrombin defect 31.0 CBS MTHFR SERPINE1
43 acute myocardial infarction 31.0 ACE CRP EDN1 SELP SERPINE1
44 diabetic angiopathy 31.0 EDN1 INS MTHFR
45 apnea, obstructive sleep 31.0 CRP EDN1 INS
46 diabetic neuropathy 30.9 ACE INS VEGFA
47 portal hypertension 30.8 EDN1 NOS3 VEGFA
48 myocardial infarction 30.8 ACE APOE CBS CRP EDN1 INS
49 heart disease 30.7 ACE APOE CRP EDN1 INS MIR21
50 pulmonary hypertension 30.6 ACE ACVRL1 EDN1 MIR21 NOS3 SERPINE1

Graphical network of the top 20 diseases related to Vascular Disease:



Diseases related to Vascular Disease

Symptoms & Phenotypes for Vascular Disease

UMLS symptoms related to Vascular Disease:


angina pectoris, chest pain, edema, flushing, leg cramps, warm skin, vein pain

MGI Mouse Phenotypes related to Vascular Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.03 PON1 SELP ACE SERPINE1 ACVRL1 VCAM1
2 homeostasis/metabolism MP:0005376 9.97 NOS3 PON1 SELP ACE SERPINE1 ACVRL1
3 liver/biliary system MP:0005370 9.56 NOS3 SELP ACE SERPINE1 ACVRL1 APOE
4 renal/urinary system MP:0005367 9.28 NOS3 SELP ACE SERPINE1 ACVRL1 APOE

Drugs & Therapeutics for Vascular Disease

Drugs for Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1223)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4,Phase 3,Phase 2 58-18-4 6010
2
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2 58-22-0 6013
3
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2 315-37-7 9416
4
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2 5949-44-0
5
Verteporfin Approved, Investigational Phase 4,Not Applicable 129497-78-5
6
Paclitaxel Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 33069-62-4 36314
7
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
8
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
9
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120202-66-6, 113665-84-2 60606
10
Ramipril Approved Phase 4,Phase 3,Phase 2,Not Applicable 87333-19-5 5362129
11
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55142-85-3 5472
12
Ustekinumab Approved, Investigational Phase 4 815610-63-0
13
Exenatide Approved, Investigational Phase 4,Phase 3 141758-74-9 15991534
14
Metformin Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 657-24-9 14219 4091
15
Esomeprazole Approved, Investigational Phase 4,Phase 1 161796-78-7, 119141-88-7 4594 9579578
16
Famotidine Approved Phase 4 76824-35-6 3325
17
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1 75614-87-8, 51-45-6 774
18
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75847-73-3 5362032 40466924
19
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76420-72-9 6917719
20
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
21
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 55-56-1 9552079 2713
22
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
23
Iodine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7553-56-2 807
24
Metronidazole Approved Phase 4 443-48-1 4173
25
Povidone Approved Phase 4,Phase 3 9003-39-8
26
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
27
Teicoplanin Approved, Investigational Phase 4 61036-62-2
28
Sevelamer Approved Phase 4 52757-95-6
29
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73963-72-1 2754
30
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274693-27-5 9871419
31
Pravastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81093-37-0 54687
32
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10102-43-9 145068 160954
33
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
34
Isoflurane Approved, Vet_approved Phase 4,Not Applicable 26675-46-7 3763
35
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 28523-86-6 5206
36
Nifedipine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21829-25-4 4485
37
Bisoprolol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 66722-44-9 2405
38
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 88150-42-9 2162
39
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
40
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-93-5 3639
41
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 144701-48-4 65999
42
Amiloride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2016-88-8, 2609-46-3 16231
43
Captopril Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 62571-86-2 44093
44
Nitrendipine Approved, Investigational Phase 4,Phase 3,Phase 2 39562-70-4 4507
45
Chlorthalidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 77-36-1 2732
46
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 79902-63-9 54454
47
Nebivolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 152520-56-4, 99200-09-6, 118457-14-0 71301
48
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 299-42-3 9294
49
Oxymetazoline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1491-59-4 4636
50
Phenylephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-42-7 6041

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Testosterone for Peripheral Vascular Disease Unknown status NCT00504712 Phase 4 Testosterone;0.9% saline
2 Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial) Unknown status NCT02092532 Phase 4 Rescue Intravitreal Aflibercept Injection
3 Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy Unknown status NCT02072408 Phase 4 aflibercept
4 Paclitaxel Eluting Balloon and Conventional Balloon for In-Stent Restenosis of the Superficial Femoral Artery Unknown status NCT01083394 Phase 4
5 Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease Unknown status NCT00986752 Phase 4
6 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part II) (DCLI-II) Unknown status NCT01173094 Phase 4
7 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part I) Unknown status NCT01171703 Phase 4
8 Comparison of Stent and Prothesis Bypass in Superficial Femoral Artery Unknown status NCT01147419 Phase 4
9 PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept Unknown status NCT02681783 Phase 4 aflibercept
10 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
11 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
12 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
13 The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
14 Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function Unknown status NCT02584075 Phase 4 Byetta (Exenatide);Glucophage ( Metformin Hydrochloride)
15 Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
16 LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients Unknown status NCT02077257 Phase 4 Rosuvastatin
17 Anti-Hypertensive Agent (ACEi) and Heart Function Improvement in Association With Rho Kinase Activity Changes in Human Unknown status NCT01069042 Phase 4 Enalapril
18 The Amputation Surgical Site Infection Trial (ASSIT) Unknown status NCT02018094 Phase 4 Co-amoxiclav;Iodine;Metronidazole;Chlorhexidine;Teicoplanin;Clindamycin
19 Graz Study on the Risk of Atrial Fibrillation Unknown status NCT01461434 Phase 4
20 How Bone is Made in Children Receiving Dialysis Unknown status NCT01799317 Phase 4 Vitamin D2
21 Safety and Efficacy Study of OmniWave Endovascular System to Treat Deep Vein Thrombosis Unknown status NCT00640731 Phase 4
22 Lovaza Mechanisms of Action Unknown status NCT01301794 Phase 4
23 Residual Platelet Activity In Advanced Peripheral Artery Disease Unknown status NCT01627431 Phase 4 Acetylsalicylic acid;Clopidogrel
24 Platelets Induced Vasodilation, in Vitro and in Vivo Study Unknown status NCT00152646 Phase 4 placebo, aspirine, clopidogrel
25 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis Unknown status NCT02033135 Phase 4
26 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROL Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease Unknown status NCT01653600 Phase 4
27 Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events Unknown status NCT00886574 Phase 4 Cilostazol;Aspirin
28 Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
29 Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy Unknown status NCT01023373 Phase 4 Medical treatment
30 Renal Denervation in Hypertension Unknown status NCT01570777 Phase 4
31 Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD Unknown status NCT02008786 Phase 4 ramipril;rosuvastatin;placebo
32 The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
33 L-arginine Treatment in Mild Hypertension Unknown status NCT02894723 Phase 4
34 Comparison of Volatile Anesthetics on Cerebral Oxygenation During Controlled Hypotension Unknown status NCT02834845 Phase 4 Sevoflurane;Desflurane
35 The Effect of the Timing of Colloid and Crystalloid Infusions on Postspinal Hypotension After Spinal Anesthesia for Caesarian Section Unknown status NCT02680678 Phase 4
36 Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension Unknown status NCT02641821 Phase 4 Nifedipine GITS
37 BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study) Unknown status NCT02398929 Phase 4 Bisoprolol 2.5 mg;Placebo
38 Colloid Preload Versus Colloid Coload During Cesarean Deliveries Unknown status NCT02393196 Phase 4 hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®);hydroxyethyl starch (%6 HES 130/0.4) (Voluven®)
39 INTERVENCION Trial Unknown status NCT02373163 Phase 4 Hydrochlorothiazide;Amlodipine;Telmisartan
40 Comparison of Single and Combination Diuretics in Low-Renin Hypertension Unknown status NCT02351973 Phase 4 Hydrochlorthiazide;Amiloride;Hydrochlorthiazide and Amiloride
41 The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy Unknown status NCT02231788 Phase 4 Telminuvo®Tab. 40/2.5mg;Telmitrend®Tab. 80mg
42 Treatment of Hypertension in Tibetan Adult Population Unknown status NCT02217852 Phase 4 Nitrendipine;Hydrochlorothiazide;Captopril,Hydrochlorothiazide;Beijing hypotensive No.0
43 Treatment of HYpertension: Morning Versus Evening Unknown status NCT02214498 Phase 4 Enalapril/hydrochlorothiazide;Placebo
44 Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
45 The Short-term Efficacy of Gastrodia and Uncaria Drink in Treating Hypertension Unknown status NCT02156024 Phase 4 Gastrodia and Uncaria Drink
46 Chlorthalidone and HCTZ Impacts on Platelet Activation Unknown status NCT02100462 Phase 4 Chlorthalidone 12.5 mg;Hydrochlorothiazide 25 mg;Aspirin 81 mg
47 The Hypotensive Effect of Metformin in Hypertensive Patients. Unknown status NCT02072382 Phase 4 Metformin;Placebo
48 Comparative Study of the Effects of Telmisartan and Nebivolol Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
49 Rosuvastatin for Preventing Complications in Renal Ablation Unknown status NCT01899027 Phase 4 Rosuvastatin;Placebo
50 Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine Unknown status NCT01840761 Phase 4 herbal drug;placebo

Search NIH Clinical Center for Vascular Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: aneurysm

Genetic Tests for Vascular Disease

Anatomical Context for Vascular Disease

MalaCards organs/tissues related to Vascular Disease:

41
Heart, Endothelial, Testes, Kidney, Eye, Lung, Liver

Publications for Vascular Disease

Articles related to Vascular Disease:

(show top 50) (show all 1897)
# Title Authors Year
1
Novel concepts for the role of smooth muscle cells in vascular disease:the need for a unifying smooth muscle cell classification. ( 29408963 )
2018
2
Suicide right ventricle after lung transplantation for pulmonary vascular disease. ( 29921031 )
2018
3
Determination of hemodynamic risk for vascular disease in planar artery bifurcations. ( 29434229 )
2018
4
Utilization and in-hospital outcomes associated with atherectomy in the treatment of peripheral vascular disease: An observational analysis from the National Inpatient Sample. ( 29466936 )
2018
5
A Nonsurgical Approach to Mesenteric Vascular Disease: Erratum. ( 29864088 )
2018
6
Peripheral vascular disease assessment in the lower limb: a review of current and emerging non-invasive diagnostic methods. ( 29751811 )
2018
7
Long-Term Prognosis of Patients With Transient Ischemic Attack or Stroke and Symptomatic Vascular Disease in Multiple Arterial Beds. ( 29880551 )
2018
8
Correction: The modality of dialysis does not influence atheromatous vascular disease progression or cardiovascular outcomes in dialysis patients without previous cardiovascular disease. ( 29953560 )
2018
9
Gene polymorphisms of fibronectin rs2289202 and fibrillin 2 rs331069 associate with vascular disease, the TAMRISK study. ( 29399340 )
2018
10
Abstracts from the 11th International Conference on Neonatal and Childhood Pulmonary Vascular Disease, 2018. ( 29897297 )
2018
11
Reversible cerebral vasoconstriction complicating cerebral atherosclerotic vascular disease in Schimke immuno-osseous dysplasia. ( 29978300 )
2018
12
<i>ALU</i>minating the Path of Atherosclerosis Progression: Chaos Theory Suggests a Role for <i>Alu</i> Repeats in the Development of Atherosclerotic Vascular Disease. ( 29895733 )
2018
13
Signalling through Src family kinase isoforms is not redundant in models of thrombo-inflammatory vascular disease. ( 29974666 )
2018
14
Is Pulmonary Vascular Disease reversible with PPAR EL agonists? ( 29432661 )
2018
15
Long-term atherosclerotic vascular disease risk and prognosis in elderly women with abdominal aortic calcification on lateral spine images captured during bone density testing: A prospective study. ( 29443425 )
2018
16
Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease. ( 29947750 )
2018
17
<i>ABCA7</i> and risk of dementia and vascular disease in the Danish population. ( 29376091 )
2018
18
Inadequate Health Literacy in Patients with Arterial Vascular Disease. ( 29891435 )
2018
19
Right Ventricular Base/Apex Ratio in the Assessment of Pediatric Pulmonary Arterial Hypertension - Results from the European Pediatric Pulmonary Vascular Disease Network. ( 29896859 )
2018
20
Nathan Bryan, PhD: Addressing the Root of Vascular Disease With Nitric Oxide. ( 29859509 )
2018
21
Pulmonary hypertension and pulmonary vascular disease: course report. ( 29928464 )
2018
22
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? ( 29945212 )
2018
23
Early Pulmonary Vascular Disease in Young Adults Born Preterm. ( 29944842 )
2018
24
Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selection-Focus on Group II Pulmonary Hypertension. ( 29417467 )
2018
25
Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. ( 29308539 )
2018
26
Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. ( 29310800 )
2018
27
Four ECG left ventricular hypertrophy criteria and the risk of cardiovascular events and mortality in patients with vascular disease. ( 29878973 )
2018
28
Association of sleep-disordered breathing with severe chronic vascular disease in patients with type 2 diabetes. ( 29859478 )
2018
29
Identifying Pain and Effects on Quality of Life from Chronic Wounds Secondary to Lower-Extremity Vascular Disease: An Integrative Review. ( 29438151 )
2018
30
Gender Differences in Peripheral Vascular Disease. ( 29628610 )
2018
31
Influence of micro- and macro-vascular disease and Tumor Necrosis Factor Receptor 1 on the level of lower-extremity amputation in patients with type 2 diabetes. ( 29879997 )
2018
32
HRCT findings of collagen vascular disease-related interstitial pneumonia (CVD-IP): a comparative study among individual underlying diseases. ( 29857950 )
2018
33
Comparisons of the Framingham and Pooled Cohort Equation Risk Scores for Detecting Subclinical Vascular Disease in Blacks Versus Whites. ( 29361288 )
2018
34
A Nonsurgical Approach to Mesenteric Vascular Disease. ( 29419563 )
2018
35
Peripheral vascular disease risk in diabetic individuals without coronary heart disease. ( 29801688 )
2018
36
Erectile dysfunction is associated with subclinical carotid vascular disease in young men lacking widely-known risk factors. ( 29442076 )
2018
37
First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension. ( 29348153 )
2018
38
Hospital readmissions in diabetic kidney transplant recipients with peripheral vascular disease. ( 29704405 )
2018
39
Identifying Pain and Effects on Quality of Life from Chronic Wounds Secondary to Lower-Extremity Vascular Disease: An Integrative Review. ( 29438143 )
2018
40
Using Omics to Understand and Treat Pulmonary Vascular Disease. ( 29881726 )
2018
41
Evolving Mechanisms of Vascular Smooth Muscle Contraction Highlight Key Targets in Vascular Disease. ( 29452094 )
2018
42
Vascular disease in COPD: Systemic and pulmonary expression of PARC (Pulmonary and Activation-Regulated Chemokine). ( 28545096 )
2017
43
Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials. ( 28403216 )
2017
44
Reply to Letter to Editor regarding the article, &amp;quot;Polyarteritis nodosa presenting as peripheral vascular disease and acute limb ischemia&amp;quot;. ( 28397743 )
2017
45
Atherosclerotic vascular diseases have really the same risk factors? Comparison between large abdominal aortic aneurysm and obstructive non-coronary arterial disease. ( 28509621 )
2017
46
Restenosis in Hemodialytic Fistulas and Chronic Kidney Disease-Associated Vascular Disease: Two Pathologies Driven by Metakaryotic Stem Cells. ( 28535522 )
2017
47
Calcium-induced conformational changes of Thrombospondin-1 signature domain: implications for vascular disease. ( 27485292 )
2017
48
Microscope-Integrated Optical Coherence Tomography Angiography in the Operating Room in Young Children With Retinal Vascular Disease. ( 28384676 )
2017
49
The emerging role of NADPH oxidase NOX5A in vascular disease. ( 28473473 )
2017
50
Black patients present with more severe vascular disease and a greater burden of risk factors than white patients at time of major vascular intervention. ( 28951156 )
2017